2026-04-17T16:18:04Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1955602026-03-26T19:46:31Zcom_2072_1057col_2072_478800col_2072_478917

Feasibility of a Multimodal Prehabilitation Programme in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer: A Pilot Study Díaz Feijoo, Berta Agustí, Núria Sebio García, Raquel López-Hernández, Antonio Siso, Marina Glickman, Ariel Carreras-Dieguez, Nuria Fuste, Pere Marina, Tiermes Martínez-Egea, Judit Aguilera, Laura Perdomo, Juan Manuel Pelaez, Amaia López-Baamonde, Manuel Navarro Ripoll, Ricard Gimeno, Elena Campero, Betina Torné Bladé, Aureli Martínez Palli, Graciela Arguis Giménez, María José Càncer d'ovari Cirurgia ginecològica Quimioteràpia del càncer Malalts de càncer Ovarian cancer Gynecologic surgery Cancer chemotherapy Cancer patients Introduction: Treatment for advanced ovarian cancer (AOC) comprises cytoreductive surgery combined with chemotherapy. Multimodal prehabilitation programmes before surgery have demonstrated efficacy in postoperative outcomes in non-gynaecological surgeries. However, the viability and effects of these programmes on patients with AOC are unknown. We aimed to evaluate the feasibility and postoperative impact of a multimodal prehabilitation programme in AOC patients undergoing surgery. Methods: This single-centre, before-and-after intervention pilot study included 34 patients in two cohorts: the prehabilitation cohort prospectively included 15 patients receiving supervised exercise, nutritional optimisation, and psychological preparation from December 2019 to January 2021; the control cohort included 19 consecutive patients between January 2018 and November 2019. Enhanced Recovery After Surgery guidelines were followed. Results: The overall adherence to the multimodal prehabilitation programme was 80%, with 86.7% adherence to exercise training, 100% adherence to nutritional optimisation, and 80% adherence to psychological preparation. The median hospital stay was shorter in the prehabilitation cohort (5 (IQR, 4-6) vs. 7 days (IQR, 5-9) in the control cohort, p = 0.04). Differences in postoperative complications using the comprehensive complication index (CCI) were not significant (CCI score: 9.3 (SD 12.12) in the prehabilitation cohort vs. 16.61 (SD 16.89) in the control cohort, p = 0.08). The median time to starting chemotherapy was shorter in the prehabilitation cohort (25 (IQR, 23-25) vs. 35 days (IQR, 28-45) in the control cohort, p = 0.03). Conclusions: A multimodal prehabilitation programme before cytoreductive surgery is feasible in AOC patients with no major adverse effects, and results in significantly shorter hospital stays and time to starting chemotherapy. 2023-03-17T18:49:32Z 2023-03-17T18:49:32Z 2022-03-23 2023-03-17T18:49:32Z info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion 2072-6694 https://hdl.handle.net/2445/195560 724414 35406407 eng Reproducció del document publicat a: https://doi.org/10.3390/cancers14071635 Cancers, 2022, vol. 14, num. 7, p. 1635 https://doi.org/10.3390/cancers14071635 cc-by (c) Díaz Feijoo, Berta et al., 2022 https://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess 12 p. application/pdf MDPI Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques)